CASI Pharmaceuticals Inc
ENM
Company Profile
Business description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Contact
No. 81, Jianguo Road
Room 1701-1702, China Central Office Tower 1
Huamao Office Building, Chaoyang District
Beijing100025
CHNT: +86 01065618789
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
233
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,815.10 | 13.60 | -0.15% |
| CAC 40 | 7,738.42 | 75.83 | 0.99% |
| DAX 40 | 23,790.11 | 116.82 | 0.49% |
| Dow JONES (US) | 44,484.42 | 10.52 | -0.02% |
| FTSE 100 | 8,774.69 | 10.64 | -0.12% |
| HKSE | 24,221.41 | 149.13 | 0.62% |
| NASDAQ | 20,393.13 | 190.24 | 0.94% |
| Nikkei 225 | 39,812.84 | 50.36 | 0.13% |
| NZX 50 Index | 12,725.64 | 58.65 | -0.46% |
| S&P 500 | 6,227.42 | 29.41 | 0.47% |
| S&P/ASX 200 | 8,578.10 | 19.60 | -0.23% |
| SSE Composite Index | 3,454.79 | 2.95 | -0.09% |